Aprea Therapeutics (APRE) Stock Price, Quote, News & History | Benzinga

Aprea Therapeutics Inc (APRE) Stock Price, Quote, News & History

APRENASDAQ

Trade with Public

Trade with Public

$0.9800

0.03013.17%

At close: Aug 26, 5:00 PM EST

$0.9404

-0.0396-4.04%

After Hours: 4:40 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$1.09

Close

$0.98

Volume / Avg.

2.74M / 153.29K

Day Range

$0.92 - $1.16

52 Wk Range

0.55 - 1.69

Market Cap

$11.84M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

79

Short Interest

0.05%

Days to Cover

1

Recent Aprea Therapeutics Inc News

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts view APRE, SRFM, CNH stocks.

Avi Kapoor

Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars

Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.

Vandana Singh

Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?

FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund clinical development and ensure company sustainability until 2026.

Vandana Singh

Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Lisa Levin

Why Aprea Therapeutics Shares Hit A New 52-Week Low Today

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock. What Else?

Henry Khederian

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-12.17M

Investing Cash Flow (TTM)

-15.40K

Financing Cash Flow (TTM)

36.89M

Free Cash Flow (TTM)

-12.18M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

24.70M

Analyst Trends and Forecast

2

Mar

2

May

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.5

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$29.52M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

0.30

Earnings Yield % (TTM)

-101.06%

Earnings Yield % (FWD)

-41.93%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.06

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$41.23M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.09

Close

$0.98

Volume / Avg.

2.74M / 153.29K

Day Range

$0.92 - $1.16

52 Wk Range

0.55 - 1.69

Market Cap

$11.84M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

79

Short Interest

0.05%

Days to Cover

1

About

Sector

Health Care

Industry

Biotechnology

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genet...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Aprea Therapeutics (APRE) stock?

A

You can purchase shares of Aprea Therapeutics (NASDAQ:APRE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Aprea Therapeutics (APRE) competitors?

A

Other companies in Aprea Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Aprea Therapeutics (APRE) stock?

A

Aprea Therapeutics has a consensus price target of $3.07.

Q

What is the current price for Aprea Therapeutics (APRE)?

A

The stock price for Aprea Therapeutics (NASDAQ: APRE) is $0.9404 last updated August 26, 2026 at 4:40 PM EDT.

Q

Does Aprea Therapeutics (APRE) pay a dividend?

A

There are no upcoming dividends for Aprea Therapeutics.

Q

When is Aprea Therapeutics (NASDAQ:APRE) reporting earnings?

A

Aprea Therapeutics does not have any upcoming earnings scheduled.

Q

Is Aprea Therapeutics (APRE) going to split?

A

There is no upcoming split for Aprea Therapeutics.

Q

What sector and industry does Aprea Therapeutics (APRE) operate in?

A

Aprea Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.